Latest Articles

Publication Date
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central

Published: Feb. 28, 2025, 10:47 a.m.
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - bmcwomenshealth.biomedcentral.com

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis bmcwomenshealth.biomedcentral.com

Published: Feb. 28, 2025, 10:47 a.m.
Predictive Significance of Glycosyltransferase-Related lncRNAs in Endometrial Cancer: A Comprehensive Analysis and Experimental Validation - ACS Publications

Predictive Significance of Glycosyltransferase-Related lncRNAs in Endometrial Cancer: A Comprehensive Analysis and Experimental Validation ACS Publications

Published: Feb. 24, 2025, 11:12 a.m.
Short-course, higher dose vaginal brachytherapy for endometrial cancer shown to be effective - MSN

Short-course, higher dose vaginal brachytherapy for endometrial cancer shown to be effective MSN

Published: Feb. 24, 2025, 4:36 a.m.
Ultrasound falls short for detecting endometrial cancer in Black women - AuntMinnie

Ultrasound falls short for detecting endometrial cancer in Black women AuntMinnie

Published: Feb. 21, 2025, 10:10 p.m.
Dr Hinchcliff on the Benefits of Chemoimmunotherapy in Endometrial Cancer - OncLive

Dr Hinchcliff on the Benefits of Chemoimmunotherapy in Endometrial Cancer OncLive

Published: Feb. 21, 2025, 9:57 p.m.
Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer - Physician's Weekly

Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer Physician's Weekly

Published: Feb. 21, 2025, 6:31 a.m.
Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial - Nature.com

Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial Nature.com

Published: Feb. 20, 2025, 9:18 p.m.
Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer - Diabetes In Control

Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer Diabetes In Control

Published: Feb. 20, 2025, 7:52 p.m.
Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer - HealthDay

Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer HealthDay

Published: Feb. 20, 2025, 4:55 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!